All lobbying filings

Tiber Creek Group

Tiber Creek Group filed a Q3 report for Takeda Pharmaceuticals America, Inc. on October 19, 2026, reporting $50,000 in lobbying income.

Lobbying for Takeda Pharmaceuticals America, Inc. · Pharmaceutical company.

As filed: TIBER CREEK GROUP for TAKEDA PHARMACEUTICALS AMERICA, INC.

All filings by Tiber Creek Group · Everything Takeda Pharmaceuticals America, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.

Bills named in this filing 1

H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.